Company Overview
- Headquarters
- Boston, MA, US
- Website
- prilenia.com
- Phone
- (972) 775-5584
- Employees
- 51
- Founded in
- 2018
- Industry
- BioTech/Drugs
- NAICS Code
-
NAICS Code 54171 CompaniesNAICS Code 541714 CompaniesNAICS Code 541 CompaniesNAICS Code 54 CompaniesNAICS Code 5417 Companies
- SIC Code
-
SIC Code 87 CompaniesSIC Code 873 Companies
Financials & Stats
Revenue
$0B
Who is Prilenia
Prilenia is a clinical-stage biotechnology company based in Boston, Massachusetts. With 51 employees, Prilenia is focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. The company's current revenue stands at $0.186 million. Prilenia's lead asset is Pridopidine, an oral drug candidate with potential applications in multiple movement disorders and neurodegenerative diseases affecting both adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in a global Phase 3 trial, known as PROOF-HD, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. Prilenia is led by Dr. Michael Hayden, a seasoned leader with a history of success in the biotechnology industry. Dr. Hayden has founded five biotech companies and previously held positions as President of Global R&D and Chief Scientific Officer at Teva, where he oversaw the development of numerous drug products. For more information about Prilenia and its work, visit their website at prilenia.com.
Company Leadership
Prilenia Tech Stack
Companies Similar to Prilenia
Analyze industry trends and opportunities by examining competitors and companies comparable to Prilenia, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 0M | 3 | Manassas, VA | 2008 | |
| 0M | 11 | Chapel Hill, NC | 1967 | |
| 0M | 39 | Florham Park, NJ | 1996 | |
| 803 | Deerfield, IL | 2010 | ||
| Buffalo, NY |